Pre Seed · Biotech · Maastricht, Netherlands · Founded 2024 · 2–10 employees
MosaMatrix is a 2024 spin-off from Maastricht University's MERLN Institute for Technology-Inspired Regenerative Medicine, developing next-generation hydrogels and bioinks for 3D cell culture and bioprinting. Their products are the first fully synthetic, dynamic bioinks on the market, offering tunable mechanical properties, excellent printability, and cell survival without animal-derived components. The company targets applications in drug discovery, regenerative medicine, and personalized cell therapy. MosaMatrix has been selected for a NWO Take-off early-stage trajectory (2025), validating both its scientific foundation and commercial potential.
No open roles listed right now.